Jade Biosciences Reports Q2 2025 Net Loss of $32.1M with No Revenue Figures Provided

Reuters
08/14
<a href="https://laohu8.com/S/JBIO">Jade Biosciences</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Net Loss of $32.1M with No Revenue Figures Provided

Jade Biosciences Inc., a biotechnology company specializing in therapies for autoimmune diseases, reported its financial results for the second quarter ending June 30, 2025. The company experienced a net loss of $32.1 million, which includes non-cash stock-based compensation of $4.0 million. Other expenses were reported at $4.4 million, influenced by a $6.2 million expense related to the change in fair value of convertible notes, partially offset by $1.8 million in interest earned from investments. Research and Development expenses reached $22.5 million, with personnel-related charges accounting for $5.7 million, including $2.6 million in non-cash stock-based compensation. General and Administrative expenses were reported at $5.2 million, with $3.1 million attributed to personnel-related costs, including $1.4 million in non-cash stock-based compensation. The company reported cash and cash equivalents totaling $220.9 million. Jade anticipates that this financial position will support its operating expenses and capital expenditure requirements through the end of 2027. In terms of business updates, Jade Biosciences highlighted the presentation of preclinical data for JADE101, its anti-APRIL monoclonal antibody aimed at treating IgA nephropathy, at the 62nd European Renal Association Congress. The company also announced plans for a Phase 1 healthy-volunteer study of JADE101, expected to commence in the third quarter of 2025, with interim data anticipated in the first half of 2026. CEO Tom Frohlich expressed confidence in the company's progress toward becoming a clinical-stage company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9511830-en) on August 13, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10